***Commonwealth of Massachusetts***

***Executive Office of Health and Human Services***

***Office of Medicaid***

[*www.mass.gov/masshealth*](http://www.mass.gov/masshealth)

MassHealth

# All Provider Bulletin 318

June 2021

**TO**: All Providers Participating in MassHealth

**FROM**: Daniel Tsai, Assistant Secretary for MassHealth [signature of Daniel Tsai]

RE: Update about Monoclonal Antibody Treatment for Coronavirus Disease 2019 (COVID-19)

## Background

This bulletin, which supplements and updates [All Provider Bulletins 304](https://www.mass.gov/lists/all-provider-bulletins) and [312](https://www.mass.gov/lists/all-provider-bulletins), provides an update to the payment provisions for monoclonal antibody treatment for COVID-19 described in those bulletins. It also notes that the U.S. Food and Drug Administration (FDA) withdrew emergency use authorization for a previously approved monoclonal antibody treatment that is no longer a covered service for MassHealth members. Finally, the FDA granted emergency use authorization for monoclonal antibody therapy sotrovimab effective May 26, 2021, and MassHealth will cover this service.

This bulletin applies to members enrolled in MassHealth fee-for-service, the Primary Care Clinician (PCC) Plan, or a Primary Care Accountable Care Organization (ACO). Information about coverage through MassHealth Managed Care Entities (MCEs) and the Program for All-inclusive Care for the Elderly (PACE) will be included in a forthcoming MCE bulletin.

## Updated Payment for Administration of Monoclonal Antibody Products

Effective for dates of service on or after May 6, 2021, providers enrolled in the MassHealth acute outpatient hospital (AOH), community health center (CHC), and physician programs may bill and receive payment for administering monoclonal antibody products used to treat COVID-19 as described in the table below. These rates, which are consistent with Medicare, will be formally established through amendments to 101 CMR 446.00: *COVID-19 Payment Rates for Certain Community Health Care Providers*.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0243 SL | $0.00 | Injection, casirivimab and imdevimab, 2400 mg |
| M0243 | $450.00 | Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring |
| M0244 | $750.00 | Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring in the home or residence |

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0245 SL | $0.00 | Injection, bamlanivimab and etesevimab, 2100 mg |
| M0245 | $450.00 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
| M0246 | $750.00 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence |

The modifier “SL” indicates state-supplied vaccine or antibodies. This modifier is to be applied to codes to identify administration of vaccines or antibodies provided at no cost, whether by the Massachusetts DPH, another federal, state, or local agency, or a manufacturer. If providers receive the antibodies from one of these sources at no cost, they must bill the code for the antibodies themselves, with modifier SL, and the codes for intravenous infusion of the antibodies. MassHealth will pay $0 for antibodies billed with the modifier SL, and will pay the rates listed above for the intravenous infusion of the antibodies.

## Update to Covered Monoclonal Antibody Products

On April 16, 2021, the FDA withdrew emergency use authorization for bamlanivimab alone as treatment for COVID-19. MassHealth will not pay for codes Q0239 SL and M0239 billed for dates of service on or after April 16, 2021.

The FDA granted emergency use authorization for monoclonal antibody therapy sotrovimab effective May 26, 2021. MassHealth will cover this service, and anticipates formally establishing rates consistent with Medicare once Medicare’s rates are available.

## MassHealth Website

This bulletin is available on the [MassHealth Provider Bulletins](http://www.mass.gov/masshealth-provider-bulletins) web page.

[Sign up](https://www.mass.gov/forms/email-notifications-for-masshealth-provider-bulletins-and-transmittal-letters) to receive email alerts when MassHealth issues new bulletins and transmittal letters.

## Questions

### Long-Term Services and Supports

Phone: (844) 368-5184 (toll free)

Email: [support@masshealthltss.com](file:///C%3A%5CUsers%5CPSousa%5CAppData%5CLocal%5CMicrosoft%5CWindows%5CINetCache%5CContent.Outlook%5C6920G7AP%5Csupport%40masshealthltss.com)

Portal: [MassHealthLTSS.com](file:///C%3A%5CUsers%5CPSousa%5CAppData%5CLocal%5CMicrosoft%5CWindows%5CINetCache%5CContent.Outlook%5C6920G7AP%5CMassHealthLTSS.com)

Mail: MassHealth LTSS

 PO Box 159108

 Boston, MA 02215

Fax: (888) 832-3006

### All Other Provider Types

Phone: (800) 841-2900; TTY: (800) 497-4648

Email: providersupport@mahealth.net

Fax: (617) 988-8974